LBPO.TB03 · 肿瘤生物学 · Late-Breaking
患者特异性食管腺癌芯片:建模肿瘤-基质-免疫相互作用与治疗反应
Patient-specific esophageal adenocarcinoma-on-a-chip: Modeling tumor-stromal-immune interactions and therapeutic response
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
引言:食管腺癌是北美食管癌死亡的主要原因,尽管采用基于紫杉烷的三联化疗,5年生存率仍然很差(15-25%)。广泛的患者间和患者内基因组异质性常常限制了基因指导下靶向治疗的有效性,并导致对化疗和免疫治疗的耐药。目前,尚无明确的指南来预测患者特异性的治疗反应。传统的动物模型和2D细胞系不能充分重现肿瘤微环境(TME),凸显了需要能够捕捉免疫细胞、癌症相关成纤维细胞(CAF)和脉管系统之间相互作用的个性化平台。在本研究中,我们开发了一种免疫功能完备的食管腺癌芯片模型,该模型纳入了基质成分和免疫细胞,并通过模拟TME内患者特异性的肿瘤-免疫相互作用来实现个性化治疗测试。
方法:将未经治疗的患者来源类器官(PDO)、匹配的CAF、自体肿瘤浸润淋巴细胞(TIL)和原代食管内皮细胞整合到双通道芯片(Emulate)中。肿瘤类器官接种于上皮通道,而CAF和内皮细胞占据基质通道,两者由多孔PDMS膜隔开。施加60 μl/h的流动和拉伸(10%,0.15 Hz)以模拟灌注和蠕动。基质单层形成后,以1000 μl/h灌注标记的TIL持续2小时。对3D微组织组织结构和TIL动态进行10天的监测。使用相同的患者来源细胞建立平行的静态transwell培养(-流动/-拉伸),以评估动态生物力学线索的影响。
结果:实时成像显示,在生理相关的流动和剪切应力下,肿瘤生长和动态TME重塑可持续长达10天。在上皮和基质通道中均观察到复杂3D微组织的渐进形成。自体TIL在基质通道内粘附、增殖并形成簇,其中一些向含肿瘤的上皮通道迁移,表明存在活跃的肿瘤-免疫串扰。匹配的静态transwell培养未能产生可比的3D基质结构或定向TIL迁移,证实了流动和周期性拉伸在基质构筑和免疫募集中的关键作用。
结论:这种患者特异性、包含TME的食管芯片平台通过捕捉生理性流动和拉伸驱动的肿瘤-免疫动态,为动物模型提供了稳健的替代方案。我们的模型能够快速地对个性化化疗和免疫治疗反应进行离体评估,提供与临床相关的结果以指导食管腺癌的精准治疗。
查看英文原文 English abstract
Introduction: Esophageal adenocarcinoma drives most esophageal cancer mortality in North America, with poor 5-year survival (15-25%) despite taxane-based triplet chemotherapy. Extensive inter- and intra-patient genomic heterogeneity often limits the effectiveness of genetically guided targeted therapies and contributes to resistance to chemotherapy and immunotherapy. Currently, no definitive guidelines exist to predict patient-specific treatment response. Conventional animal models and 2D cell lines inadequately recapitulate the tumor microenvironment (TME), underscoring the need for personalized platforms that capture interactions among immune cells, cancer-associated fibroblasts (CAFs), and the vasculature. In this study, we developed an immune-competent esophageal adenocarcinoma-on-a-chip model that incorporates both stromal components and immune cells and enables personalized therapy testing by simulating patient-specific tumor-immune interactions within the TME.
Methods: Treatment-naive patient-derived organoids (PDOs), matched CAFs, autologous tumor-infiltrating lymphocytes (TILs), and primary esophageal endothelial cells were integrated into a two-channel chip (Emulate). Tumor organoids were seeded in the epithelial channel, while CAF and endothelial cells occupied the stromal channel, separated by a porous PDMS membrane. Flow at 60 µl/h and stretch (10%, 0.15 Hz) were applied to mimic perfusion and peristalsis. After stromal monolayer formation, labeled TILs were perfused for 2 hours at 1000 µl/h. 3D microtissue organization and TIL dynamics were monitored for 10 days. Parallel static transwell cultures (-flow/-stretch) using the same patient-derived cells were established to assess the impact of dynamic biomechanical cues.
Results: Real-time imaging demonstrated tumor growth and dynamic TME remodeling for up to 10 days under physiologically relevant flow and shear stress. Progressive formation of complex 3D microtissues was observed in both epithelial and stromal channels. Autologous TILs adhered within the stromal channel, proliferated, and formed clusters, with some migrating toward the tumor-containing epithelial channel, indicating active tumor-immune crosstalk. Matched static transwell cultures failed to generate comparable 3D stromal structures or directional TIL migration, confirming the critical role of flow and cyclic stretch in stromal architecture and immune recruitment.
Conclusion: This patient-specific, TME-inclusive esophagus-on-a-chip platform offers a robust alternative to animal models by capturing physiological flow and stretch-driven tumor-immune dynamics. Our model enables rapid ex vivo assessment of personalized chemotherapy and immunotherapy responses, offering clinically relevant results to guide precision treatment in esophageal adenocarcinoma.
利益披露 Disclosure
M. Al Dow, None..
S. Pal, None..
C. Julien, None..
A. Staravoitava, None..
A. Brassard, None..
B. Giannias, None..
N. Bertos, None..
K. Ma, None..
L. Ferri, None..
J. Cools Lartigue, None.